Brought to you by 
NanoBio brings in $12mm via Series B; adds $10mm
09 Jul 2009
Executive Summary
NanoBio (dermatological products, anti-infectives, and intranasal vaccines) raised $12mm through its Series B financing to returning shareholder Perseus LLC and other existing backers. The company will use the money for Phase I trials of its topical acne treatment and intranasal seasonal influenza vaccine, and preclinical development of a nebulized cystic fibrosis therapy.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Nasal
- Topical Delivery
-
Biotechnology
- Drug Discovery Tools
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NanoBio brings in $12mm via Series B; adds $10mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice